Lexeo Therapeutics Q3 Earnings Call Highlights

Lexeo Therapeutics (NASDAQ:LXEO) reported interim data from a small, early-stage trial of its gene therapy LX2020, saying patients who received the higher dose showed reductions in abnormal heart rhythms and improvements in other measures of PKP2-associated arrhythmogenic cardiomyopathy.

The company also said the Food and Drug Administration is open to using a measure of abnormal heart rhythm as a surrogate endpoint in a pivotal study seeking accelerated approval. Lexeo plans to begin that study in the second half of 2027, though the design and regulatory details remain under discussion.

Higher-dose patients showed reductions in arrhythmias

In the open-label Phase 1/2 HEROIC-PKP2 study, seven participants received the higher dose of LX2020 and three received a lower dose. As of the October 15 data cutoff, follow-up ranged from nine to 24 months, and six of the seven higher-dose participants had reached at least one year of follow-up.

At their latest assessments, the higher-dose group had a mean 80% reduction in nonsustained ventricular tachycardia, or NSVT, burden and a mean 44% reduction in premature ventricular contraction, or PVC, burden, Chief Medical Officer Nani Bhalla said. NSVT declined in six of seven higher-dose participants, while PVCs declined in five.

Bhalla said five of the seven higher-dose participants reported symptom improvement, and five showed improvement in right ventricular free wall strain, a measure of heart muscle function. Mean strain improved from an abnormal baseline of negative 15% to negative 19% at 12 months, she said. Right and left ventricular ejection fraction remained stable in most participants.

At 12 months, five of six higher-dose participants had fewer than one NSVT episode per day on average. At their latest visits, all seven were below that threshold, Bhalla said.

Lexeo compared the trial results with its SNAPSHOT natural history study, in which mean NSVT burden increased 53% over 12 months. The company cautioned that the studies did not have identical inclusion criteria. Chief Executive Officer R. Nolan Townsend said the treatment study had greater enrichment of patients with NSVT burden at baseline.

Bhalla also said one higher-dose participant began taking the antiarrhythmic drug flecainide three months after treatment. She said the participant’s reduction in arrhythmias exceeded what the company would have expected from that medication alone.

Pivotal study design remains under discussion

Lexeo estimates the pivotal study would include approximately 60 to 80 patients across treatment and control populations. Townsend said the company assumes a 12-month endpoint for accelerated approval and hopes to follow the same patients longer to support full approval.

The proposed analysis would compare the proportion of patients above or below the NSVT threshold in treatment and control groups, rather than measuring change from baseline. Lexeo also expects to include PVC burden and implantable cardioverter defibrillator, or ICD, events as additional measures.

Townsend said the type of control group, statistical plan and confirmatory evidence strategy remain to be finalized with the FDA. He said the company expects to continue those discussions in the first half of next year.

Participants in HEROIC-PKP2 were required to have an ICD and a minimum PVC burden. Lexeo expects to retain most of those criteria for the pivotal study, although Townsend said the company has more work to do on how to address baseline NSVT burden in enrollment.

Safety and portfolio priorities

Bhalla said LX2020 was generally well tolerated across the 10 participants, with no clinically significant complement activation, no study discontinuations and no new treatment-related serious adverse events.

Townsend said previously reported liver enzyme elevations occurred shortly after dosing, were managed under the study protocol and resolved. He also said the study had one previously reported treatment-related serious adverse event involving sustained ventricular tachycardia in a participant with a history of the condition.

Outside the LX2020 program, Townsend said Lexeo had enrolled 26 participants in its CLARITY-FA study of LX2006. Chief Financial Officer Louis Tamayo said the company had just under $220 million in cash and would review portfolio priorities as it looks for ways to advance LX2020 with its existing resources.

About Lexeo Therapeutics (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.